Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains

This publication has 43 references indexed in Scilit:

• New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo
  Cancer Immunology, Immunotherapy, 2024
• Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
  The Lancet, 2021
• Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells
  Molecular Pharmaceutics, 2018
• Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
  Molecular Therapy, 2018
• Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion
  Cytotherapy, 2017
• The immune synapse clears and excludes molecules above a size threshold
  Nature Communications, 2014
• Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents
  Cancer Letters, 2013
• Properties, production, and applications of camelid single-domain antibody fragments
  Applied Microbiology and Biotechnology, 2007
• A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks
  Nature, 1995
• Naturally occurring antibodies devoid of light chains
  Nature, 1993